The stock of Adaptive Biotechnologies Corp (ADPT) has seen a 28.50% increase in the past week, with a 14.48% gain in the past month, and a 51.62% flourish in the past quarter. The volatility ratio for the week is 13.22%, and the volatility levels for the past 30 days are at 7.86% for ADPT. The simple moving average for the last 20 days is 13.57% for ADPT’s stock, with a simple moving average of 32.68% for the last 200 days.
Is It Worth Investing in Adaptive Biotechnologies Corp (NASDAQ: ADPT) Right Now?
ADPT has 36-month beta value of 1.44. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ADPT is 142.33M, and currently, short sellers hold a 6.77% ratio of that float. The average trading volume of ADPT on October 03, 2024 was 1.23M shares.
ADPT) stock’s latest price update
Adaptive Biotechnologies Corp (NASDAQ: ADPT)’s stock price has soared by 2.39 in relation to previous closing price of 5.02. Nevertheless, the company has seen a gain of 28.50% in its stock price over the last five trading days. globenewswire.com reported 2024-08-29 that clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies
Analysts’ Opinion of ADPT
Many brokerage firms have already submitted their reports for ADPT stocks, with JP Morgan repeating the rating for ADPT by listing it as a “Overweight.” The predicted price for ADPT in the upcoming period, according to JP Morgan is $15 based on the research report published on July 05, 2023 of the previous year 2023.
Scotiabank, on the other hand, stated in their research note that they expect to see ADPT reach a price target of $15. The rating they have provided for ADPT stocks is “Sector Outperform” according to the report published on January 05th, 2023.
Piper Sandler gave a rating of “Overweight” to ADPT, setting the target price at $14 in the report published on December 21st of the previous year.
ADPT Trading at 13.63% from the 50-Day Moving Average
After a stumble in the market that brought ADPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.05% of loss for the given period.
Volatility was left at 7.86%, however, over the last 30 days, the volatility rate increased by 13.22%, as shares surge +18.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +22.38% upper at present.
During the last 5 trading sessions, ADPT rose by +28.50%, which changed the moving average for the period of 200-days by -0.77% in comparison to the 20-day moving average, which settled at $4.57. In addition, Adaptive Biotechnologies Corp saw 4.90% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADPT starting from Taylor Stacy L, who sale 26,922 shares at the price of $4.50 back on Aug 22 ’24. After this action, Taylor Stacy L now owns 139,365 shares of Adaptive Biotechnologies Corp, valued at $121,079 using the latest closing price.
STACY L TAYLOR, the Officer of Adaptive Biotechnologies Corp, proposed sale 26,922 shares at $4.50 during a trade that took place back on Aug 22 ’24, which means that STACY L TAYLOR is holding shares at $121,079 based on the most recent closing price.
Stock Fundamentals for ADPT
Current profitability levels for the company are sitting at:
- -1.09 for the present operating margin
- 0.5 for the gross margin
The net margin for Adaptive Biotechnologies Corp stands at -1.26. The total capital return value is set at -0.37. Equity return is now at value -66.96, with -31.64 for asset returns.
Based on Adaptive Biotechnologies Corp (ADPT), the company’s capital structure generated 0.37 points at debt to capital in total, while cash flow to debt ratio is standing at -0.91. The debt to equity ratio resting at 0.59. The interest coverage ratio of the stock is -36.6.
Currently, EBITDA for the company is -179.38 million with net debt to EBITDA at -1.01. When we switch over and look at the enterprise to sales, we see a ratio of 5.48. The receivables turnover for the company is 4.58for trailing twelve months and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.99.
Conclusion
To put it simply, Adaptive Biotechnologies Corp (ADPT) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
